Acute graft-versus-host disease (GVHD) is effected by donor T lymphocytes which have been stimulated by host antigens. Activated donor T lymphocytes express interleukin-2 receptor (IL-2R), which is comprised of three subunits (␣, ␤, ␥). During activation, the ␣ IL-2R subunit (CD25) is shed from the receptor complex and can be measured in the circulation. Soluble IL-2R␣ (sIL-2R) levels are increased in states of immune activation including GVHD, and could theoretically be used as a guide to therapy. Since IL-2R␣ expression is an early marker of T cell activation, we investigated: (1) if an increase in sIL-2R is specific for acute GVHD; and (2) if serial sIL-2R levels can identify patients with early GVHD, prior to the onset of clinical tissue damage (effector function). Weekly sIL-2R levels were monitored in 36 patients undergoing matched related (n ‫؍‬ 23) or matched unrelated (n ‫؍‬ 13) allogeneic bone marrow transplantation (BMT). There was no significant difference in sIL-2R levels between matched related and matched unrelated recipients. Patients with acute GVHD (n ‫؍‬ 19, 53%) demonstrated higher sIL-2R levels, than those without during weeks 2 and 3 post-BMT (P ‫؍‬ 0.02 and 0.04, Mann-Whitney U test, twotailed). In patients with acute GVHD, the rise in sIL-2R preceded the clinical signs of GVHD (16/19 patients). However, patients with sepsis demonstrated a trend towards higher sIL-2R levels at week 1 and significantly greater levels by week 4 (P = 0.02). Furthermore, patients with veno-occlusive disease (VOD) (25%) also had significantly higher sIL-2R levels at week 2 (P ‫؍‬ 0.03). We conclude that although sIL-2R levels increase in patients with acute GVHD, similar increases are seen in patients with VOD and/or sepsis and therefore, as a single biochemical marker, we find that serial measurements of sIL-2R lacks sufficient specificity to guide GVHD therapy. Keywords: graft-versus-host disease; soluble interleukin-2 receptor; bone marrow transplantation As a consequence of allogeneic BMT, acute GVHD continues to be associated with significant morbidity and mortality.
As a consequence of allogeneic BMT, acute GVHD continues to be associated with significant morbidity and mortality. 1 GVHD occurs in 50% of HLA-identical sibling transplants and in up to 80% of matched unrelated transplants. 2, 3 GVHD is graded according to the extent and pattern of organ involvement (skin, liver and gut). 4 Pathology in acute GVHD involves immunocompetent donor T lymphocytes which have been activated during myeloablative therapy. Myeloablative therapy causes a release of cytokines resulting in increased expression of host minor antigens, which are then recognised by donor T lymphocytes. 5 Currently, a specific biochemical marker of GVHD is not available, and diagnosis and treatment is based on clinical signs demonstrating target organ damage. Most therapies for prophylaxis and treatment of acute GVHD reduce cytotoxic T cells. Although activated donor T lymphocytes play an important role in the development of GVHD, immunohistochemical analysis demonstrates that effector cells in GVHD are natural killer cells. 6, 7 Consequently, it may be advantageous to control GVHD and initiate therapy at an earlier stage of immune activation, prior to effector activity. A laboratory marker capable of demonstrating early T cell expansion and activation, may therefore be useful in the diagnosis and early management of acute GVHD.
Interleukin-2 (IL-2) is secreted from activated T cells in GVHD and other immunological processes. [8] [9] [10] The identification of activated IL-2 secreting T cells can accurately predict which patients will develop GVHD after a histocompatible related transplant. 11 Early in the process of activation, T cells express the IL-2 receptor (IL-2R). The IL-2 receptor has three subunits (␣, ␤, ␥) that are encoded by different genes. 12 Components of the receptor are present on natural killer cells, monocytes and lymphocytes. Although the combination of IL-2R␤ and ␥ can bind IL-2, the expression of all three chains (including the ␣ chain) is required for the high affinity state. During expression of the high affinity receptor, IL-2R␣ is shed from the cell surface and can be measured in the circulation by enzymelinked immunosorbent assay (ELISA). 13 Serial measurements of serum IL-2R␣ (sIL-2R) following solid organ transplantation correlate with development of organ rejection. 14, 15 Serial sIL-2R levels have also been used as a marker of immune activation in various chronic autoimmune diseases. 16 Since GVHD is a systemic T cell response, a marked increase in sIL-2R levels should correlate and precede clinical GVHD. Serum sIL-2R levels measured in patients following related allogeneic BMT have been found to correlate with the presence of GVHD and this marker could potentially be useful as a guide to early anti-GVHD therapy. 10, 17 To investigate this potential, we measured serial sIL-2R levels in patients undergoing allogeneic BMT to determine: (1) if elevated sIL-2R levels are specific for GVHD, and (2) if a rise in the level of sIL-2R can identify patients with pre-clinical GVHD (T cell activation phase) prior to effector function and tissue damage.
Materials and methods

sIL-2R enzyme-linked immunosorbent assay (ELISA)
Serum IL-2R␣ concentrations were measured using a commercially available ELISA (Genzyme Diagnostics, Cambridge, MA, USA). Diluted standards and unknown samples were added to strips precoated with immobilized mouse monoclonal antibody to IL-2R␣. Biotinylated polyclonal rabbit anti-IL-2R␣ antibody was added and incubated at 37°C for 2 h. After washing, a peroxidase-labeled streptavidin reagent was added and tetramethyl benzidine (TMB) used as a substrate. Plates were incubated for 15 min in the dark and were read at 450 nm on a Biotek Instruments Microplate reader (Biotek Instruments, Winooski, VT, USA) with linear analysis from plotted standards.
Patients
Following informed consent, 36 patients undergoing allogeneic BMT between January 1995 and March 1997 were enrolled. Thirty-three patients received an unmanipulated marrow transplant and three patients received mobilized peripheral blood progenitors (PBP). Twenty-three patients had donors which were matched related and 13 patients had marrow from a matched unrelated donor. There were 21 males and 15 females diagnosed with chronic myelogenous leukemia (CML, n = 16), acute myelogenous leukemia (AML, n = 7), multiple myeloma (MM, n = 4), chronic lymphocytic leukemia (CLL, n = 2), acute lymphoblastic leukemia (ALL, n = 2), non-Hodgkin's lymphoma (NHL, n = 3), aplastic anemia (AA, n = 1) and myelodysplastic syndrome (MDS, n = 1). Median age was 45 (range 18-60). GVHD prophylaxis consisted of cyclosporin and methotrexate on days 1, 3, 6 and 11. Additional prophylaxis for unrelated transplant recipients involved methylprednisolone at 1 mg/kg starting on day 7 or 0.5 mg/kg on day 7 and increased to 1 mg/kg on day 15. Acute GVHD was graded according to Glucksberg criteria. 4 When possible, a skin biopsy was used to diagnose and confirm skin GVHD. In addition to GVHD, veno-occlusive disease (VOD) was monitored. Veno-occlusive disease was clinically defined by right upper quadrant pain, weight gain, ascites and early hyperbilirubinemia. 18 Episodes of sepsis, determined by the presence of positive cultures, were also monitored.
Five normal healthy volunteers were assayed and demonstrated an average sIL-2R level of 980 pg/ml (range 800-1220 pg/ml). This was consistent with the reported normal range of the test (500-2250 pg/ml). Serial sIL-2R levels (pre, week 1, week 2, week 3 and week 4) from all BMT patients were coded and stored (−70°C). Batched samples were measured and the results grouped according to the type of BMT and the presence or absence of clinical GVHD. In addition to monitoring clinical features of GVHD, the day at which steroids were started as anti-GVHD therapy was recorded as a clinical endpoint. Clinical assessments of GVHD were made without knowledge of the sIL-2R results.
Statistical analysis
All data points were entered into a statistical package program (Statistix; Analytical Software, Tallahassee, FL, USA). Two-tailed Mann-Whitney U tests were performed using the same statistical package. Mean and standard error data were also calculated from this data base.
Results
sIL-2R levels in matched related and matched unrelated BMT
The pattern of sIL-2R expression for all patients is shown in Figure 1 . Levels of sIL-2R prior to marrow or PBP infusion, designated 'pre', were lower (2114 pg/ml Ϯ 211, mean Ϯ s.e.) than values over the next 4 weeks. The highest sIL-2R levels were seen during week 2 (6155 pg/ml Ϯ 618). Levels of sIL-2R for matched related (n = 23) and matched unrelated recipients (n = 13) did not differ significantly at any time-point evaluated ( Figure 2 ). 
Levels of sIL-2R in patients with acute GVHD
Nineteen of 36 patients (53%) developed acute GVHD within the study period (0-30 days). There were higher levels of sIL-2R in patients with GVHD as compared to those without ( Figure 3 ). Using two-tailed Mann-Whitney U tests, significant differences were noted during the 2nd and 3rd weeks (P = 0.02, P = 0.03). Mean sIL-2R levels during week 2 were 4922 pg/ml Ϯ 953 (mean Ϯ s.e.) for patients with no GVHD and 7319 pg/ml Ϯ 880 for patients who subsequently developed GVHD. Although sIL-2R levels in patients with GVHD increased, and were highest during the 2nd week (days 7-14), the signs of clinical GVHD and the day at which steroids were initiated occurred 18 Ϯ 4 days post-transplant. On average, there was a 4.8-fold increase in sIL-2R levels at week 2 when compared to the pre-marrow infusion level (pre) for patients developing GVHD. Patients without GVHD had a 2.9-fold average increase in sIL-2R at week 2. Fourteen out of 36 patients had a four-fold or greater increase in sIL-2R from baseline to week 2 and of these patients, 11 (78%) went on to develop GVHD. The remaining three patients in this group (22%) had VOD.
Influence of sepsis on sIL-2R levels
Approximately one half (19/36) of the patients demonstrated blood culture positive sepsis on at least one occasion during the first month post-transplant. In this group a trend towards higher sIL-2R levels was seen at week 1 (4701 pg/ml Ϯ 778 vs 2919 pg/ml Ϯ 476, P = 0.08), week 2 (7317 pg/ml Ϯ 872 vs 4989 pg/ml Ϯ 811, P = 0.10), and week 3 (6554 pg/ml Ϯ 794 vs 5175 pg/ml Ϯ 773, Patients were monitored over the first 30 days post-transplant. Statistically higher sIL-2R levels were evident during weeks 2 and 3 (Mann-Whitney U test, two-tailed) in patients who developed GVHD. Therapy for GVHD was started on day 18 (Ϯ4), whereas the rise in IL-2R was seen prior to clinical GVHD during week 2 (days 7-14) in 16 of 19 patients. P = 0.27). Statistical significance was seen at week 4 (5033 pg/ml Ϯ 555 vs 3073 pg/ml Ϯ 452, P = 0.03) as shown in Figure 4 . The incidence of GVHD in patients with and without sepsis was 58% and 47%, respectively.
Veno-occlusive disease and sIL-2R levels post-BMT
Nine of 36 patients developed clinical evidence of VOD during the first month post-transplant. Patients with VOD demonstrated a higher sIL-2R level at week 2 than those without VOD (P = 0.02). Based on our analysis there was no statistical difference in sIL-2R levels for patients with VOD as compared to those with GVHD ( Figure 5 ). An elevated sIL-2R at week 2 did not differentiate patients with VOD from those developing GVHD. Patients negative for both VOD and GVHD (VOD−/GVHD−) had statistically significant lower sIL-2R levels than GVHD−/VOD+ (P = 0.02, week 2) and GVHD+/VOD− patients (P = 0.001, week 2 and 0.01, week 3) (Figure 6 ).
Discussion
The diagnosis and management of acute GVHD is based on clinical evidence alone. This can be problematic as clinical manifestations of target organ involvement are not always specific for GVHD. Although biopsy results can be useful Figure 4 The role of sepsis on sIL-2R levels. Patients with positive blood cultures ˿ (n = 19) (0-30 days) were compared to patients with negative cultures (n = 17). Although there was a trend towards septic patients having higher IL-2R levels, statistical significance was seen during week 4. in confirming GVHD, there is often uncertainty regarding the presence of GVHD and whether potentially toxic immunosuppressive therapy should be started. A biochemical marker that demonstrates early T cell activation and is specific for GVHD may have clinical utility, not only in predicting or confirming the onset of GVHD, but also in assessing the response to therapy. Siegert et al 10 previously investigated sIL-2R levels following BMT in 17 patients undergoing matched related BMT. Increased sIL2R levels were seen in patients who developed grades II-IV GVHD (n = 12). Patients with fever lasting more than 6 days in the early transplant period also had elevated sIL-2R levels and it was concluded that although serial sIL-2R values correlate with acute GVHD, elevations in sIL-2R were also influenced by sepsis. Recently, Miyamoto et al 17 found that monitoring serial IL-2R levels was useful in following acute GVHD. In this analysis of 30 allogeneic BMT patients, the severity of GVHD correlated with the level of sIL-2R. No patients evaluated had documented bacterial infection and as a result this variable was not analyzed.
In agreement with previous investigators, we found a statistical difference in sIL-2R levels between patients with acute GVHD (within the first 30 days post-BMT) and those without GVHD. This difference was maximal during week 2 (days 7-14) and preceded the onset and subsequent treatment of GVHD (average, day 18). As a result, an sIL-2R level measurement taken during week 2 (demonstrating at least a four-fold increase from baseline) was predictive for about 60% of patients that would go on to develop GVHD. In theory, it may be interesting to investigate if initiating immunosuppressive therapy at an earlier time-point is more efficacious in influencing outcome in acute GVHD. At present treatment with steroids, conventional first-line therapy in patients who have developed clinical signs of acute GVHD, is effective in only 40% of patients. 19 Although monitoring sIL-2R levels post-transplant was able to identify patients prior to the onset of clinical GVHD, other post-transplant clinical conditions were also associated with a significant rise in sIL-2R. From our analysis we are in agreement with the conclusions of Siegert et al 10 and find that bacterial infections are a confounding variable in the interpretation of sIL-2R levels. The correlation between sepsis and increased sIL-2R has been previously described in non-transplant patients. 20, 21 Approximately one half of our patients had documented bacterial infections and in this group significantly higher sIL-2R levels were noted during week 4. In addition to bacterial infections one should note that viral pathogens, such as cytomegalovirus, can also cause an increase in sIL-2R. 22 In our current analysis, we focused on a period of time where bacterial, rather than viral infections, would be of clinical significance (days 0-30).
In addition to bacterial infections, we also conclude that VOD is associated with a marked elevation in sIL-2R. From our analysis, serial sIL-2R measurements did not discriminate patients with VOD from patients developing GVHD. The reason for elevated sIL-2R levels during VOD is not clear, but may be related to: (1) non-specific increased cytokine expression following regimen-related tissue damage, or (2) coincident sepsis associated with significant organ failure.
In conclusion we find sIL-2R levels increase prior to the onset of acute GVHD, however increases in sIL-2R are also seen in patients with VOD and/or sepsis and without specificity for GVHD, it is difficult to consider serial sIL-2R levels as a potential guide to GVHD therapy.
